Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol 2022 Dec 22:JCO2201725. doi: 10.1200/JCO.22.01725.
PMID: 36548927